Phase I trial of sorafenib in combination with IFN alpsh-2a in patients with unresectable and/or metastatic renal cell carcinoma or malgnant melanoma - Escudier, B; Lassau, N; Angevin, E (Clin Cancer Res, 2007)
et al.